drugset / Trial / NCT00102622
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Phase 1
Terminated
18 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will also be studied. Researchers will also ask the patients if they will allow additional tumor samples to be collected and extra blood samples to be drawn. These samples will be used to learn about the biological response before and after treatment.
Timeline
- Start
- 2004-12-01
- Primary completion
- 2012-07
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped: “Phase I/II study that did not progress to Phase II”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | tgDCC-E1A | Unknown | 1.8 mg/m2 | Other |